Stocktoria
REPLIGEN CORP RGEN
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 1986-04-29
REPLIGEN CORP financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $738.3M | $634.4M | $632.4M | $801.5M | $670.5M |
| R&D expense | $54.2M | $43.2M | $42.7M | $43.9M | $34.3M |
| SG&A expense | $290.5M | $263.4M | $218.6M | $215.8M | $183.9M |
| Operating income | $55.2M | -$35.1M | $47.7M | $224.7M | $167.2M |
| Interest expense | — | — | $2.0M | $1.2M | $11.3M |
| Income tax | $13.5M | -$1.5M | $21.1M | $33.2M | $25.3M |
| Net income | $48.9M | -$25.5M | $35.6M | $186.0M | $128.3M |
| EPS (diluted) | $0.86 | $-0.46 | $0.63 | $3.24 | $2.24 |
| Operating cash flow | $117.4M | $175.4M | $113.9M | $172.1M | $119.0M |
| Free cash flow | $93.9M | $149.7M | $77.7M | $87.2M | $51.9M |
| Cash & equivalents | $566.0M | $757.4M | $751.3M | $523.5M | $603.8M |
| Inventory | $170.5M | $143.0M | $202.3M | $238.3M | $184.5M |
| Total assets | $2.9B | $2.8B | $2.8B | $2.5B | $2.4B |
| Total liabilities | $843.6M | $856.9M | $866.3M | $614.0M | $608.3M |
| Shareholders' equity | $2.1B | $2.0B | $2.0B | $1.9B | $1.8B |
Source: SEC EDGAR filings · CIK 0000730272 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.